Suspected side effects should be reported via the MHRA Yellow Card scheme
Registry-only trials were assessed as unclear risk of bias, as critical JBI domains, such as completeness of outcome data, appropriateness of analysis, and selective reporting, cannot be evaluated without peer-reviewed results
After intracerebral hemorrhage, the HDAC1/2 inhibitor Lomidesine (FK228) can alter microglial heterogenization, reduce neuroinflammation, and alleviate neuronal ferroptosis, possibly through regulating the Nrf2/HO-1 signaling pathway
In the Diabetes Therapy journal, researchers from the DZD and Helmholtz Munich provide an overview of these new diabetes and obesity drugs
Retatrutide acts as a triple receptor agonist, simultaneously targeting the three receptors that play crucial roles in metabolic regulation